Published in FASEB J on January 31, 2011
Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov (2015) 1.90
Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int (2012) 1.86
Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease. Am J Physiol Renal Physiol (2012) 1.58
JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab (2012) 1.56
Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab (2013) 1.49
Engraftment of Human Glioblastoma Cells in Immunocompetent Rats through Acquired Immunosuppression. PLoS One (2015) 1.39
Mechanisms of muscle wasting in chronic kidney disease. Nat Rev Nephrol (2014) 1.21
Role of satellite cells versus myofibers in muscle hypertrophy induced by inhibition of the myostatin/activin signaling pathway. Proc Natl Acad Sci U S A (2012) 1.18
Decreased miR-29 suppresses myogenesis in CKD. J Am Soc Nephrol (2011) 1.15
Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med (2011) 1.15
Regulation of muscle protein synthesis and the effects of catabolic states. Int J Biochem Cell Biol (2013) 1.10
MicroRNA in myogenesis and muscle atrophy. Curr Opin Clin Nutr Metab Care (2013) 1.04
Blocking Notch in endothelial cells prevents arteriovenous fistula failure despite CKD. J Am Soc Nephrol (2014) 1.04
Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem (2015) 1.03
Muscle wasting from kidney failure-a model for catabolic conditions. Int J Biochem Cell Biol (2013) 1.00
Signal regulatory protein-α interacts with the insulin receptor contributing to muscle wasting in chronic kidney disease. Kidney Int (2013) 0.98
Sarcopenic obesity: how do we treat it? Curr Opin Endocrinol Diabetes Obes (2013) 0.98
Satellite cells in human skeletal muscle plasticity. Front Physiol (2015) 0.96
Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care (2013) 0.96
Myostatin suppression of Akirin1 mediates glucocorticoid-induced satellite cell dysfunction. PLoS One (2013) 0.96
Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr Opin Support Palliat Care (2011) 0.96
Low-frequency electrical stimulation attenuates muscle atrophy in CKD--a potential treatment strategy. J Am Soc Nephrol (2014) 0.90
Migration of smooth muscle cells from the arterial anastomosis of arteriovenous fistulas requires Notch activation to form neointima. Kidney Int (2015) 0.89
Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle (2015) 0.88
Inhibition of myostatin in mice improves insulin sensitivity via irisin-mediated cross talk between muscle and adipose tissues. Int J Obes (Lond) (2015) 0.88
Differential muscle hypertrophy is associated with satellite cell numbers and Akt pathway activation following activin type IIB receptor inhibition in Mtm1 p.R69C mice. Am J Pathol (2014) 0.87
Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease. J Am Soc Nephrol (2014) 0.87
Acupuncture plus low-frequency electrical stimulation (Acu-LFES) attenuates denervation-induced muscle atrophy. J Appl Physiol (1985) (2015) 0.87
Acupuncture plus Low-Frequency Electrical Stimulation (Acu-LFES) Attenuates Diabetic Myopathy by Enhancing Muscle Regeneration. PLoS One (2015) 0.87
Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications. Tissue Eng Part B Rev (2014) 0.85
A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice. J Am Soc Nephrol (2013) 0.85
Saturated fatty acid palmitate-induced insulin resistance is accompanied with myotube loss and the impaired expression of health benefit myokine genes in C2C12 myotubes. Lipids Health Dis (2013) 0.84
Skeletal muscle atrophy is attenuated in tumor-bearing mice under chemotherapy by treatment with fish oil and selenium. Oncotarget (2015) 0.83
Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study. BMC Nephrol (2013) 0.82
Relationship between Blood Myostatin Levels and Kidney Function:Shimane CoHRE Study. PLoS One (2015) 0.82
Molecular mechanisms of insulin resistance in chronic kidney disease. Kidney Int (2015) 0.82
Progressive inflammation and wasting in patients with ESRD. Clin J Am Soc Nephrol (2014) 0.80
Diets for patients with chronic kidney disease, should we reconsider? BMC Nephrol (2016) 0.80
Insulin resistance and muscle metabolism in chronic kidney disease. ISRN Endocrinol (2013) 0.79
Can muscle-kidney crosstalk slow progression of CKD? J Am Soc Nephrol (2014) 0.79
Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective. J Cachexia Sarcopenia Muscle (2015) 0.79
Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle (2015) 0.78
Serum Glucocorticoid-Regulated Kinase 1 Blocks CKD-Induced Muscle Wasting Via Inactivation of FoxO3a and Smad2/3. J Am Soc Nephrol (2016) 0.77
Uremic myopathy: is oxidative stress implicated in muscle dysfunction in uremia? Front Physiol (2015) 0.76
Inhibiting myostatin signaling prevents femoral trabecular bone loss and microarchitecture deterioration in diet-induced obese rats. Exp Biol Med (Maywood) (2015) 0.76
Toll-like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease. J Cachexia Sarcopenia Muscle (2016) 0.75
Glucocorticoid-Regulated Kinase: Linking Azotemia and Muscle Wasting in CKD. J Am Soc Nephrol (2016) 0.75
Suppression of muscle wasting by the plant-derived compound ursolic acid in a model of chronic kidney disease. J Cachexia Sarcopenia Muscle (2016) 0.75
Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease. PLoS One (2016) 0.75
A non-human primate model of radiation-induced cachexia. Sci Rep (2016) 0.75
Protein Nutrition and Malnutrition in CKD and ESRD. Nutrients (2017) 0.75
Myostatin Activates the Ubiquitin-Proteasome and Autophagy-Lysosome Systems Contributing to Muscle Wasting in Chronic Kidney Disease. Oxid Med Cell Longev (2015) 0.75
MicroRNA-Regulated Proinflammatory Cytokines in Sarcopenia. Mediators Inflamm (2016) 0.75
Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci Rep (2016) 0.75
Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth. Mol Ther Nucleic Acids (2016) 0.75
The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques. FASEB J (2014) 0.75
The pathway to muscle fibrosis depends on myostatin stimulating the differentiation of fibro/adipogenic progenitor cells in chronic kidney disease. Kidney Int (2016) 0.75
The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy. Sci Rep (2017) 0.75
Phenotypes of Obesity: How it Impacts Management. Curr Gastroenterol Rep (2017) 0.75
MicroRNA-23a and MicroRNA-27a Mimic Exercise by Ameliorating CKD-Induced Muscle Atrophy. J Am Soc Nephrol (2017) 0.75
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature (1997) 14.82
Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell (2004) 11.33
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med (2005) 10.88
A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet (2006) 8.37
Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med (2004) 7.80
The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell (2004) 7.60
A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet (1997) 7.15
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J (2004) 7.02
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell (2010) 5.23
Functional improvement of dystrophic muscle by myostatin blockade. Nature (2002) 5.10
Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol (2004) 4.69
Induction of cachexia in mice by systemically administered myostatin. Science (2002) 4.39
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol (2006) 4.01
Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol (2003) 3.25
Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann Neurol (2002) 3.03
Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest (2004) 2.98
A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol (2008) 2.95
IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab (2004) 2.82
IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. Kidney Int (2005) 2.78
The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest (1996) 2.39
Loss of myostatin expression alters fiber-type distribution and expression of myosin heavy chain isoforms in slow- and fast-type skeletal muscle. Muscle Nerve (2005) 2.23
Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J (2005) 2.14
Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci U S A (1998) 2.13
Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell Physiol (2006) 2.13
Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol (2004) 2.13
IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol (2009) 1.88
Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol (2006) 1.82
Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci U S A (2004) 1.79
Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol (2010) 1.77
Skeletal muscle myostatin mRNA expression is fiber-type specific and increases during hindlimb unloading. Am J Physiol (1999) 1.68
Mechanisms for defects in muscle protein metabolism in rats with chronic uremia. Influence of metabolic acidosis. J Clin Invest (1987) 1.60
Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest (2009) 1.51
Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase. Cancer Res (2005) 1.48
Myofibrillar protein synthesis in myostatin-deficient mice. Am J Physiol Endocrinol Metab (2005) 1.43
Characterization of 5'-regulatory region of human myostatin gene: regulation by dexamethasone in vitro. Am J Physiol Endocrinol Metab (2001) 1.39
Regulation of GDF-8 signaling by the p38 MAPK. Cell Signal (2005) 1.32
Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes (2009) 1.31
Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: phosphorylation of p65 by IkappaB kinase and ribosomal kinase. Circ Res (2005) 1.23
AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther (2007) 1.17
Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem (2010) 1.14
Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet (2009) 1.09
Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. J Endocrinol (2000) 1.07
Receptor-mediated endocytosis of albumin by kidney proximal tubule cells is regulated by phosphatidylinositide 3-kinase. J Clin Invest (1998) 1.04
Effect of insulin on amino acid uptake and protein turnover in skeletal muscle from septic rats. Evidence for insulin resistance of protein breakdown. Arch Surg (1987) 0.99
Plasma myostatin-immunoreactive protein is increased after prolonged bed rest with low-dose T3 administration. J Gravit Physiol (1999) 0.85
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J (2004) 7.02
Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest (2003) 6.30
Cachexia: a new definition. Clin Nutr (2008) 5.49
Restoring the density-gradient expansion for exchange in solids and surfaces. Phys Rev Lett (2008) 5.28
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell (2010) 5.23
Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell (2010) 5.05
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol (2006) 4.01
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Inhibition of platelet activation by clopidogrel prevents hypertension-induced cardiac inflammation and fibrosis. Cardiovasc Drugs Ther (2013) 3.32
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest (2004) 2.98
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology (2006) 2.62
Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int (2009) 2.60
Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J Biol Chem (2001) 2.52
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell (2011) 2.30
Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int (2002) 2.27
Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest (2005) 2.24
Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol (2004) 2.13
Mitochondrial integrity and function in atherogenesis. Circulation (2002) 1.94
Mechanical stretch simulates proliferation of venous smooth muscle cells through activation of the insulin-like growth factor-1 receptor. Arterioscler Thromb Vasc Biol (2007) 1.94
IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol (2009) 1.88
Understanding mitochondrial complex I assembly in health and disease. Biochim Biophys Acta (2011) 1.86
Transcription factor FoxO1, the dominant mediator of muscle wasting in chronic kidney disease, is inhibited by microRNA-486. Kidney Int (2012) 1.86
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol (2006) 1.82
The precision of estimating protein intake of patients with chronic renal failure. Kidney Int (2002) 1.81
Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol (2010) 1.77
Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol (2010) 1.73
Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Cardiovasc Res (2012) 1.71
Genetic deficiency of adiponectin protects against acute kidney injury. Kidney Int (2013) 1.71
Proinflammatory protein CARD9 is essential for infiltration of monocytic fibroblast precursors and cardiac fibrosis caused by Angiotensin II infusion. Am J Hypertens (2011) 1.67
γδT Cell-derived interleukin-17A via an interleukin-1β-dependent mechanism mediates cardiac injury and fibrosis in hypertension. Hypertension (2014) 1.59
Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr (2010) 1.55
Requirement of argininosuccinate lyase for systemic nitric oxide production. Nat Med (2011) 1.54
Genes that confer the identity of the renin cell. J Am Soc Nephrol (2011) 1.52
Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest (2009) 1.51
Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab (2013) 1.49
Antiapoptotic effect of serum and glucocorticoid-inducible protein kinase is mediated by novel mechanism activating I{kappa}B kinase. Cancer Res (2005) 1.48
Problematic Internet Use in high school students in Guangdong Province, China. PLoS One (2011) 1.47
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant (2011) 1.44
A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep (2013) 1.44
Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS One (2012) 1.43
Interleukin-6/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration. J Biol Chem (2012) 1.41
Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney Int (2004) 1.40
Intestinal epithelial vitamin D receptor signaling inhibits experimental colitis. J Clin Invest (2013) 1.38
Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood (2011) 1.36
Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res (2010) 1.33
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol (2013) 1.32
Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int (2002) 1.31
Chemokine CXCL16 regulates neutrophil and macrophage infiltration into injured muscle, promoting muscle regeneration. Am J Pathol (2009) 1.30
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther (2010) 1.27
Aberrant neurites and synaptic vesicle protein deficiency in synapsin II-depleted neurons. Science (1994) 1.27
Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Mol Cancer Ther (2003) 1.26
CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. J Am Soc Nephrol (2011) 1.24
Evidence for adipose-muscle cross talk: opposing regulation of muscle proteolysis by adiponectin and Fatty acids. Endocrinology (2007) 1.24
Dual pathways for nuclear factor kappaB activation by angiotensin II in vascular smooth muscle: phosphorylation of p65 by IkappaB kinase and ribosomal kinase. Circ Res (2005) 1.23
Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology (2007) 1.23
Suppression of synapsin II inhibits the formation and maintenance of synapses in hippocampal culture. Proc Natl Acad Sci U S A (1995) 1.19
A comparison of classification methods for predicting Chronic Fatigue Syndrome based on genetic data. J Transl Med (2009) 1.18
IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis. J Immunol (2004) 1.18
Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function. Kidney Int (2009) 1.17
Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. J Am Soc Nephrol (2006) 1.15
Decreased miR-29 suppresses myogenesis in CKD. J Am Soc Nephrol (2011) 1.15
Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am J Physiol Heart Circ Physiol (2010) 1.15
Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J Biol Chem (2011) 1.15
Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem (2010) 1.14
FGF is essential for both condensation and mesenchymal-epithelial transition stages of pronephric kidney tubule development. Dev Biol (2006) 1.14
Serum-glucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation and cardiac fibrosis. Arterioscler Thromb Vasc Biol (2012) 1.14
PTEN expression contributes to the regulation of muscle protein degradation in diabetes. Diabetes (2007) 1.12
Lymphotoxin-independent expression of TNF-related activation-induced cytokine by stromal cells in cryptopatches, isolated lymphoid follicles, and Peyer's patches. J Immunol (2007) 1.11